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Abstract 
BACKGROUND: Th17 cells are blamed for being accused in the pathogenesis of acute myeloid leukaemia. Th17 
cells are CD4+ cell subtype. They produce IL-17A and IL-17F. 
AIM: This study aims to trace the relation between IL-17A and IL-17F polymorphisms and AML incidence and to 
define the connection between IL-17 polymorphisms and its serum level. 
METHODS: A group of 100 acute myeloid leukaemia patients and 100 age and sex-matched healthy subjects 
(controls) were enrolled in the present work. Restriction fragment length polymorphism- polymerase chain 
reaction (PCR-RFLP) was done to detect IL-17A (rs2275913; G197A) and IL-17F (rs763780; A7488G). Serum IL-
17 level was assessed by Enzyme-linked immunosorbent assay analysis (ELISA) in both patients and controls. 
RESULTS: IL-17F, IL-17A mutant genotypes and alleles showed no significant relation with acute myeloid 
leukaemia incidence. Also, ELISA results proved that serum IL-17 did not vary between acute myeloid leukaemia 
patients and healthy subjects. 
CONCLUSION: Interleukin-17 gene polymorphisms did not consider a risk for acute myeloid leukaemia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
IL-17 is an essential pro-inflammatory 
cytokine released by memory CD4 positive T cells, 
that includes six members (IL-17 A to F) binding to 
five receptors. IL-17 is important in innate as well as in 
acquired immune reactions [1]. IL-17 is promoted by 
microbial metabolites; it enhances tumour 
enlargement through angiogenic functions [2]. 
 Previous studies proved that altered values 
of IL-17 were involved in gastrointestinal and female 
genital system cancers [3], [4].
 
The IL-17A (rs2275913; G197A) 
polymorphism is blamed for being involved in 
autoimmune diseases, chronic inflammatory diseases, 
and malignancies. It induces the secretion of 
inflammatory chemokines as well as the release of 
cytokines stored in macrophages and neutrophils [5]. 
Interleukin-17F [rs763780; A7488G], is a 
second member of the IL-17 family. It has an 
important role in neutrophil functions by secreting 
different types of both cytokines and chemokines. IL-
17F rs763780 polymorphism suppresses the wild IL-
17F activities and contributes to increasing 
susceptibility to tumours. Previous studies proposed 
Basic Science 
_______________________________________________________________________________________________________________________________ 
 
_______________________________________________________________________________________________________________________________ 
1426                                                                                                                                                                                              https://www.id-press.eu/mjms/index 
 
the role of IL-17A and IL-17F gene polymorphism in 
the development of different types of tumours [6], [7]. 
The present work aimed to state the 
relationship between the mutant genotypes of IL-17A 
(rs2275913; G197A) & IL-17F [rs763780; A7488G] 
and AML susceptibility, as well as, ELISA estimation 
of IL-17 in Egyptian AML patients.  
 
 
Material and Methods 
 
The present research was done on 100 adult 
Egyptian (de novo) AML cases; samples were 
collected in the period between May 2014 to 
December 2016 from the Department of Medical 
Oncology, Kasr Al-Aini Hospital.  
Patients were 64 males and 36 females with 
age range: 21-71 years and a mean of 47 years. One 
hundred age, sex and ethnic-matched healthy 
individuals were in-rolled in the present protocol as 
control subjects.  
Informed consents were signed by all study 
groups before their participation in the research. The 
study has been approved by the committee of the 
Clinical Pathology department as well as the Internal 
Medicine department, Kasr Al Aini, Cairo University. 
All procedures performed in studies involving human 
participants were in accordance with the ethical 
standards of the institutional and/or national research 
committee and with the 1964 Helsinki declaration and 
its later amendments or comparable ethical standards. 
Diagnosis of AML was based on 
morphological examination of bone marrow aspirate. 
Immunophenotyping and Cytogenetic studies were 
assessed for subtyping of the disease. 
The demographic data of the patients were 
summarised (Table 1). 
Table 1: The demographic data of AML patients 
Item Number (100) 
Sex Male 64 
Female 36 
Age < 60 79 
≥ 60 21 
Hepatomegaly 23 
Splenomegaly 35 
Lymphadenopathy Cervical 54 
Axillary 6 
Inguinal 13 
Submandibular 50 
Abdominal 3 
Mesenteric 2 
Par aortic 2 
Medical history 32 
Family history 9 
FAB M1/M2 40 
M3 44 
M4/M5 11 
M6 3 
M7 2 
Outcome Died 41 
Others CR
* 
15 
PR
** 
29 
Relapse 15 
CR
*
-complete remission; PR
*
-partial remission. 
 
The diseased group was classified 
morphologically according to the French- American-
British (FAB) classification. 
Assessment of Interleukin-17A [rs2275913; 
G197A] and Interleukin-17F [rs763780; A7488G] 
polymorphisms by polymerase chain reaction-
restriction fragment length polymorphism (PCR-RFLP) 
technique: 
Three millilitres of blood were withdrawn 
aseptically from the study groups on EDTA. Human 
DNA extraction was done using commercial Kit 
(Fermentas Life Sciences), according to the 
manufacturer’s instructions. Genetic detection of the 
SNPs was done as previously stated [8]. 
 As regard to IL-17A (rs2275913; G197A), the 
following primers Forward 5´- 
AACAAGTAAGAATGAAAAGAGGACATGGT-3´ 
Reverse 5´ - CCCCCAATGAGGTCATAGAAGAATC -
3´ were used. For IL-17F [rs763780; A7488G], 
genotyping was performed by using Forward primer 
5´-ACCAAGGCTGCTCTGTTTCT-3´ Reverse primer 
5´-GGTAAGGAGTGGCATTTCTA-3´. 
 All PCR reactions were tested in f 25 μl 
volume; containing Master Mix (GeneON), forward 
and reverse primers, distilled water, and genomic 
extracted DNA. 
The thermocycler program applied for IL-17A 
(rs2275913; G197A) was 33 cycles at 96°C for 5 min, 
followed by 60 s at 95°C, 60 s at 65°C, 50 s at 72°C 
with a terminal extension step at 72°C for 7 min. 
[9]
 
The thermocycler program applied for IL-17F 
[rs763780; A7488G] was 35 cycles at 94°C for 3 min, 
then 30 s at 94°C, 30 s at 60°C, 30 s at 72°C with a 
final extension step at 72°C for 7 min [9]. 
The amplified product of IL-17A (rs2275913; 
G197A) was digested with XagI (Fermentas Life 
Sciences). The wild-type GG produced two bands of 
68 and 34 bp, while the polymorphic GA hetero-type 
produced three fragments of 102, 68 and 34 bp and 
the AA polymorphic homotype produced one band at 
102 bp. 
The PCR product of IL-17F [rs763780; 
A7488G] was digested with NIaIII (Fermentas Life 
Sciences); and yields one band in the case of wild 
(AA) 143 bp, three bands for AG variant 143, 80 and 
63 bp, and two bands for the GG variant 80 and 63 
bp.  
Polymorphic genetic analysis was duplicated 
twice on 42 samples to ensure quality control. These 
samples were blindly interpreted by different experts, 
who showed 100% accordance in results. 
  Enzyme-linked immunosorbent assay (ELISA) 
for serum IL-17:  
Serum samples were withdrawn from both 
study groups. IL-17 levels were measured by 
Enzyme-linked immunosorbant assay (ELISA) (R&D 
Systems, USA). Calibrations and results were 
repeated twice. Least detectable concentration of IL-
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17 was < 15 pg/ ml. 
 
Statistical analysis 
Candidates’ information was analysed by the 
statistical package SPSS version 21. Results were 
illustrated by the mean and standard deviation for 
quantitative variables and relative frequencies for a 
group’s variables. Comparison between genotype of 
both study groups was performed using binary logistic 
regression. Odds ratio (OR) with 95% confidence 
intervals was calculated. Comparison of quantitative 
variables was made using unpaired student t-test. 
Chi-square (
2
) test was calculated to compare 
groups’ data. If the expected frequency is less than 5, 
Exact test was used. P value < 0.05 was taken as 
statistically significant. Data of ELISA were analysed 
by Mann-Whitney U test. 
 
 
Results 
 
All patients and controls have been tested for 
IL-17F [A7488G] and IL-17A (rs2275913; G197A) 
polymorphisms, using PCR-RFLP technique. 
The frequency of the polymorphisms under 
research in AML patients and controls is illustrated in 
Table II. Mutants subtypes prevalence of IL-17A 
[G197A], and IL-17F [A7488G] in controls was in 
accordance with the Hardy–Weinberg equilibrium (P > 
0.05).  
The frequency of different polymorphic 
genotypes and alleles of the studied SNPs are 
illustrated in Table II. Statistical analysis showed that 
IL-17F [rs763780; A7488G] polymorphic genotype, as 
well as the polymorphic allele (G allele), was detected 
in 29/100 (29%) and 37/100 (18.5%) of patients 
respectively while it was detected in 43/100 (43%) and 
62/100 (31%) respectively in controls. The incidence 
of IL-17F polymorphic genotype, as well as the 
polymorphic allele (G allele), was significantly lower in 
AML patients when compared to controls (p = 0.039) 
and (p = 0.004) respectively. 
Otherwise, no significant relation was found 
between the patients’ groups regarding sex and 
laboratory data (data not shown). 
No statistical relation was found between AML 
patients owning the normal or the mutant genotypes 
of IL-17A (rs2275913; G197A) as regards their sex, 
clinical data, and laboratory findings (data not 
presented). Despite the higher frequency of the IL-
17A (rs2275913; G197A) heterozygous genotype 
observed in patients compared to controls, yet no 
statistical relationship was proved (p-value 0.077) 
(Table 2). 
Table 2: Frequency of IL-17F [rs763780; A7488G] and IL-17A 
(rs2275913; G197A) genotypes in patients and controls 
 
 
Gene 
Group Odd ratio 95% 
confidence 
interval 
P-
value Controls  
(n = 100) 
Patients  
(n = 100) 
N (%) N (%) 
IL-17F [rs763780; A7488G] 
Wild type (AA) 57 (57%) 71 (71%) Reference   
Heterotype 
(AG) 
24 (24%) 21 (21%) 0.702 0.335-
1.389 
0.309 
Homotype (GG) 19 (19%) 8 (8%) 0.338 0.138-
0.829 
0.015 
Mutant allele 
(G) 
62 (31%) 37 (18.5%) 0.505 0.317-
0.805 
0.004 
polymorphic 
genotype 
(AG/GG) 
43 (43) 29 (29) 0.541 0.301-
0.973 
0.039 
IL-17A (rs2275913; G197A) 
Wild type (GG) 30 (30) 31 (31) Reference   
Heterotype 
(GA) 
10 (10) 23 (23) 2.226 0.908-
5.454 
0.077 
Homotype (AA) 60 (60) 46 (46) 0.742 0.394-
1.396 
0.354 
Mutant allele 
(A) 
130 (65%) 115 (57.5) 0.729 0.486-
1.091 
0.124 
Polymorphic 
genotype 
(GA/AA) 
70 (70) 69 (69) 0.954 0.522-
1.742 
0.898 
 
There was no significant relationship between 
the combined IL-17F [rs763780; A7488G] & IL-17A 
[rs2275913; G197A] polymorphism and the incidence 
of AML between patients and controls (Table 3). 
Table 3: Combined effects of interleukin IL-17F [rs763780; A748
8G]and IL-17A (rs2275913; G197A) genotypes 
Combined 
Genotypes 
Controls (n = 100) 
No. (%) 
Cases (n = 100) 
No. (%) 
p-value 
Dual IL-17F [rs763780; A7488G] 
and IL-17A [rs2275913; G197A] 
polymorphism 
27 (27%) 18 (18%) 0.231 
 
IL-17 level was positively detected in 14 /100 
AML patients (range, mean ± SD: 1.37–19.10, 8.8 ± 
7.19 pg/ml), and 2 /100 in the control group (of level 
1.4 pg/ml). No significant relationships were observed 
regarding IL-17 levels and AML incidence (data not 
shown). 
 
 
Discussion 
 
Th17 cells with their secretory cytokines are 
considered essential controllers in inflammatory and 
autoimmune disorders. They represent a curious 
research point. Many studies proposed the potential 
effect of Th17 cells on solid tumours but their role in 
haematological malignancies is still under 
investigations [10]. 
In the present research, the association of 
AML with IL-17A and IL-17F gene polymorphic 
genotypes was assessed, as well as, ELISA 
estimation of IL-17 in AML patients. The results 
proved that IL-17F and IL-17A gene polymorphism did 
not correlate with AML incidence. These findings were 
first reported in Egyptian patients. Also, the study 
concluded that the serum level of IL-17 is not elevated 
in patients group.  
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Regarding IL-17F; our results were in contrast 
to [9] and [11] who stated that IL-17F [rs763780; 
A7488G] polymorphism was proved to be correlated 
with a predisposition to AML in Poland and China 
respectively. IL-17F G homozygous genotype was 
significantly more frequently observed among patients 
than healthy individuals. 
The study did not prove a significantly 
elevated level of IL-17 in AML patients. Our finding 
was in agreement with an earlier study conducted by 
Kawaguchi et al., who proposed that the IL-17 
expression and activity may be affected in 
polymorphic G allele owners [12].  
IL17-A had no impact on AML incidence; as 
there was no significant relation between cases and 
controls, regarding polymorphic genotype and mutant 
allele (p-value 0.898 and 0.124) respectively. This 
finding was in agreement with [13].  
Espinoza et al. proved that T lymphocytes 
from normal individuals revealed an elevated level of 
IL-17 protein after provoking A allele [14].
 
However, 
we were not able to prove the significant differences 
concerning IL-17A polymorphism and IL-17 level (data 
not shown). Also, we did not find a significant 
relationship between the IL-17 levels in AML patients 
and healthy controls, as observed in previous studies 
[11], [15].
 
Wu et al. found that an increase in IL-17 
concentration is associated with an elevation in Th17 
cell number in the patient group. It is inhibited in cases 
with complete response undergoing therapy [8].
 
Abusamra et al. proposed that the number of 
circulating Th17 cells significantly increased in ALL 
and AML patients compared with controls. These 
patients showed a decrease number of ofTh17 cell 
number when reaching complete remission after 
therapy [10].
 
On the other hand, Tian et al. indicated 
that compared with normal controls, IL-17 level 
decreased obviously in acute lymphoblastic leukaemia 
patients [16].
 
Variation in results may be due to the 
difference of patient ethnic groups, the correlation 
between IL-17F polymorphic genotypes. Also, plasma 
IL-17 values might be correlated to racial variations 
[11].
 
To our knowledge, the published data on the 
role of the IL-17F and IL-17A polymorphisms in AML 
are limited [9]; thus, our report is considered a novel 
finding not previously studied in Egyptian population. 
The authors did not contribute Il-17 polymorphism to 
the disease incidence in Egyptian cases with AML. 
Respectively, these results should be re-assessed in 
a more extended study, including multicentric patients. 
In conclusion, although Interleukin-17 is as 
important in the pathogenesis of inflammation and 
oncogenesis, yet we did not find a significant 
association between IL-17 polymorphism and 
increased susceptibility to acute myeloid leukaemia 
incidence. Further studies are indeed needed to prove 
our study conclusion. 
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